Pete Nicholas
Pete Nicholas
certainty clearly johnson objective offer per potential providing share superior today upside value
Our $80 per share offer for Guidant is compelling. We are providing Guidant shareholders with certainty of completion, significant upside potential and substantially more value today than the Johnson & Johnson transaction. By any objective measure, our offer is clearly superior to Johnson & Johnson's.
ability boston customer highly patients pioneer relationships scientific share strong talented therapies
Guidant and Boston Scientific share an entrepreneurial spirit, highly talented employees, strong customer relationships and an ability to pioneer lifesaving therapies for patients around the world.
advance expand further growth markets opportunity provides strategy unique
This transaction provides a unique opportunity to advance our strategy to further diversify and to expand the growth markets we serve.